<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582254</url>
  </required_header>
  <id_info>
    <org_study_id>AOR14101</org_study_id>
    <secondary_id>2014-002597-37</secondary_id>
    <nct_id>NCT03582254</nct_id>
  </id_info>
  <brief_title>Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years</brief_title>
  <acronym>LOCALYSE</acronym>
  <official_title>Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients older than 60 years account for half of cases of Primary Central Nervous System
      Lymphoma (PCNSL) and have a poorer outcome. No prognostic or predictive factors exist for
      survival after initial remission. 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose -
      Positron Emission Tomography ([18F]FDG-PET) plays a key role in grading and therapy
      monitoring of systemic diffuse large B-cell type.

      LOCALYZE is an ancillary Positron Emission Tomography / Magnetic Resonance (PET/MR) clinical
      study from BLOCAGE 01 (Pr Hoang-Xuan). The aim is to evaluate the usefulness of [18F]FDG-PET
      to monitor treatment response in PCNSL older than 60 years (n=56), in complement to
      multiparametric Magnetic Resonance Imaging (MRI).

      Hypothesis The investigators assume that the development of new imaging biomarker extracted
      from PET imaging and multiparametric MRI, could improve the assessment of treatment response
      in PCNSL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière
      Hospital:

        -  prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine
           and cytarabine) (PET#1),

        -  after two chemotherapy cycles (PET#2),

        -  at the end of the first-line chemotherapy regimens (PET#3).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Anticipated">May 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival calculated from the date of completion of the end of chemotherapy PET</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the predictive value of [18F]FDG-PET assessment performed at the end-of-treatment (high-dose methotrexate based polychemotherapy), on progression free survival in newly diagnosed PCNSL with age ≥60 years (n=56).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>[18F]-FDG PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]-FDG PET/MR</intervention_name>
    <description>[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:
prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),
after two chemotherapy cycles (PET#2),
at the end of the first-line chemotherapy regimens (PET#3).</description>
    <arm_group_label>[18F]-FDG PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed primary cerebral lymphoma

          -  Age ≥60 years

          -  Pathology proven diagnosis or positive cytology of the Cerebrospinal Fluid (CSF) or
             vitreous

          -  Karnofsky Performance Status ≥40

          -  No evidence of systemic Non-Hodgkin lymphomas (NHL) (body CT scan, bone marrow biopsy)

          -  Adequate haematological, renal and hepatic function

          -  Calculated creatinine clearance &gt; 40 ml/min

        Exclusion Criteria:

          -  Uncontrolled diabetes with fasting glycaemia &gt; 200 mg/dL

          -  Sensitivity to active substance in [18F]-FDG

          -  Calculated creatinine clearance &lt; 40 ml/min

          -  No contraindication to MRI (magnetic resonance imaging)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurélie KAS, Dr</last_name>
    <phone>01 42 17 62 81</phone>
    <email>aurelie.kas@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Odile HABERT, Dr</last_name>
    <phone>01 42 17 62 81</phone>
    <email>habert@imed.jussieu.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie KAS, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

